Drug Profile

TP 2846

Alternative Names: TP-2846

Latest Information Update: 23 Sep 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Tetraphase Pharmaceuticals
Class Antineoplastics; Tetracyclines
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Discontinued Acute myeloid leukaemia

Most Recent Events

23 Sep 2022 Discontinued - Preclinical for Acute myeloid leukaemia in USA (IV) (La Jolla Pharmaceutical Company website, September 2022)
28 Jul 2020 Tetraphase Pharmaceuticals has been acquired by La Jolla Pharmaceutical Company
31 Dec 2019 TetraPhase Pharmaceuticals intends to submit an IND application for TP 2846, following partner identification

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com